Standard clinical practice is built around identifying values outside of reference ranges. That approach answers "are you a statistical outlier?" — but it was never designed to answer "how worried should I be, and what should I do about it?" A CMiQCertified practitioner is trained to bridge that gap.
A CMiQCertified practitioner uses the Fatty Liver Index, insulin resistance markers, and GGT — tools that identify early hepatic fat accumulation in the 30–40% of cases where standard enzyme values are completely normal. You cannot address a risk you cannot see.
Training covers the full relationship between hepatic dysfunction and cardiovascular risk — including the atherogenic lipid pattern, inflammatory markers, insulin resistance, and blood pressure that together define cardiometabolic strain. The liver is not assessed in isolation. It is assessed as the hub it actually is.
CMiQCertified training specifically addresses early-stage detection and reversal-oriented clinical management. Most cases reach a practitioner too late because standard screening missed the early window. A trained practitioner is looking for it proactively — not waiting for an obvious signal.
A comprehensive assessment produces an actionable clinical picture — not just a list of values. Training covers evidence-based intervention pathways including dietary protocol, movement strategy, and targeted metabolic support, calibrated to your specific risk pattern rather than a generic recommendation.
The same multi-domain assessment that identifies risk is used to monitor response to intervention. As the research confirms, regression of fatty liver is associated with measurable reduction in cardiovascular risk — and a CMiQCertified practitioner has the framework to see that improvement in the data, not just in how you feel.
A CMiQCertified practitioner will have clear, substantive answers to all three. The answers tell you immediately whether the practitioner is equipped to evaluate your full picture — or working from a partial one.
This question separates practitioners who screen for fatty liver from those who test for liver damage. The FLI identifies early fat accumulation — the stage that matters most for reversal — using markers that standard enzyme panels don't include.
Insulin resistance is the primary metabolic driver of fatty liver. Fasting glucose alone misses it in most early cases. A practitioner who measures fasting insulin and calculates HOMA-IR is working upstream of the problem — which is where reversal begins.
Reversal is measurable — but only if the right markers are being tracked. A practitioner who can answer this question with specific biomarker targets and a follow-up framework has a structured approach to outcomes. One who cannot is managing by feel rather than data.
Practitioners listed in our directory have completed advanced cardiometabolic training through the CMiQCertified program. Each listing shows which certifications they hold, their care modality, and how to reach them directly.
Practitioners listed have completed advanced cardiometabolic training through the CMiQCertified program. This directory does not represent the exclusive approach to fatty liver management.